Monitor the EHA 2026 poster presentation on June 13 for any data that could de-risk EVX-04 and attract partnership interest. The clinical trial application in H2 2026 is the next major catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $4.17entry
- T+1 · 6mo ago −0.24%α −0.82% · $4.16
- T+5 · 6mo ago −1.92%α −2.00% · $4.09
- T+20 · 5mo ago −9.11%α −7.39% · $3.79
- T+60 · 3mo ago −28.18%α −32.56% · $3.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced a poster presentation at the EHA 2026 Congress detailing preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine. The data supports progression toward clinical testing, with a clinical trial application planned for H2 2026. This is a positive pipeline update but remains early-stage and non-revenue generating.
Key Facts
- EVX-04 is an off-the-shelf therapeutic AML vaccine targeting endogenous retrovirus (ERV) tumor antigens.
- Preclinical data will be presented at EHA 2026 Congress on June 13, 2026.
- Evaxion plans to submit a clinical trial application in the second half of 2026.
- EVX-04 prevented tumor growth in preclinical tumor models.
- AML is the most frequent leukemia, with a median age at diagnosis of 68 years and poor survival rates.
Financial Impact
No financial data disclosed; preclinical stage with no revenue impact.
Risk Factors
- EVX-04 is still preclinical; clinical failure risk is high.
- Evaxion has no approved products and requires additional capital to fund development.
- Competition from other AML therapies could limit commercial potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293006 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers